Merck to Participate at the Morgan Stanley Global Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BMO Incrementally More Positive on Merck (MRK) as Omarigliptin Met Primary Endpoint in Phase 3
September 16, 2015 2:53 PM EDTBMO Capital affirms Merck (NYSE: MRK) with an Outperform rating and $70 price target following news that omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, achieved its primary efficacy endpoint in a Phase 3 study. Omarigliptin was found to be non-inferior to Mercks once-daily DPP-4 inhibitor, JANUVIA® (sitagliptin), at reducing patients A1C* levels from baseline, with similar A1C reductions achieved in both groups.
Analyst Alex Arfaei commented: Based on impressive data in... More
Merck (MRK) Announces Omarigliptin Phase 3 Met Primary Endpoint in Type 2 Diabetes
September 16, 2015 10:17 AM EDTMerck (NYSE: MRK) announced that omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, achieved its primary efficacy endpoint in a Phase 3 study. Omarigliptin was found to be non-inferior to Mercks once-daily DPP-4 inhibitor, JANUVIA® (sitagliptin), at reducing patients A1C* levels from baseline, with similar A1C... More
